Information Provided By:
Fly News Breaks for January 28, 2020
Jan 28, 2020 | 10:38 EDT
Piper Sandler analyst Tyler Van Buren says that TRuE-AD2 - the first of Incyte's two pivotal topical rux studies in atopic derm - hitting its primary endpoint "is of course positive news," but it is impossible to know how positive the outcome is until he sees the data presentation at an upcoming medical meeting. While the details are "incredibly limited," the analyst maintains his positive stance on topical rux as he awaits the upcoming data presentation. Van Buren has an Overweight rating and a $95 price target on the shares.